Business Context and Reporting Period
This Form 8-K filing by Helix Acquisition Corp. II (not Bridgebio Oncology Therapeutics, Inc.) reports the consummation of its Initial Public Offering (IPO) on February 13, 2024, with the report date of February 8, 2024. The company is a Cayman Islands-based special purpose acquisition company (SPAC) focused on identifying and merging with a target business.
Key Financial Metrics
- Public Offering Proceeds: Sold 18,400,000 Class A ordinary shares at $10.00 per share, generating gross proceeds of $184,000,000.
- Private Placement Proceeds: Sold 509,000 Class A ordinary shares to the Sponsor at $10.00 per share, generating gross proceeds of $5,090,000.
- Total Trust Account: A total of $184,000,000 (net proceeds from IPO and private placement) was deposited into a U.S.-based trust account.
- Debt and Liquidity: The filing does not provide specific debt figures or operating cash flow metrics, as the company is in the pre-business combination phase. Liquidity is primarily held in the trust account.
Material Changes
The primary material change is the transition from a private entity to a publicly traded company on The Nasdaq Stock Market LLC under the symbol "HLXB." This includes the issuance of public shares, the establishment of a trust account, and the appointment of new independent directors.
Outlook, Risks, and Management Commentary
- Business Combination Timeline: The Company has 24 months from the closing of the IPO to consummate an initial business combination. If unsuccessful, public shares will be redeemed.
- Trust Account Restrictions: Funds in the trust account generally cannot be released until the completion of a business combination, a redemption event, or specific tax/dissolution expense withdrawals (up to $100,000 of interest).
- Corporate Governance: Two new independent directors, Mark C. McKenna and John Schmid, were appointed to the Board, Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee.
- Share Structure: The Sponsor holds 4,600,000 Class B Ordinary Shares following a share capitalization. Private Placement Shares held by the Sponsor are subject to transfer restrictions until 30 days after a business combination.
Investor Verification Checklist
- Verify the exact closing date of the IPO (February 13, 2024) versus the report date (February 8, 2024).
- Confirm the total amount held in the trust account ($184,000,000) and the conditions for its release.
- Review the Sponsor's commitment to waive redemption rights for Private Placement Shares in specific scenarios.
- Check the 24-month deadline for completing a business combination and the associated redemption obligations.
- Confirm the composition of the Board of Directors and the staggered terms of office for the three classes of directors.